Accuray cyberknife® system real world data and clinical studies show benefits in treatment of neurological indications

Sunnyvale, calif. , july 12, 2022 /prnewswire/ -- accuray incorporated (nasdaq: aray) announced today that new clinical studies presented at the 15th congress of the international stereotactic radiosurgery society (isrs) in milan, italy reinforce the value of the company's cyberknife® platform in the treatment of neurological indications with non-invasive radiosurgery.
ARAY Ratings Summary
ARAY Quant Ranking